Multi-Centre European Experience with Intragastric Balloon in Overweight Populations: 13 Years of Experience
- 920 Downloads
The request to lose weight is expanding not only in obese and morbidly obese patients but also in overweight patients affected by co-morbidities as diabetes and hypertension and who do not tolerate diet regimen or lifestyle changes. The aim of this study is a multicenter evaluation of outcomes of intragastric balloon in overweight patients.
Patients (BMI 27–30 kg/m2) treated with a BioEnterics Intragastric Balloon (BIB) between 1996 and 2010 were extracted from the database of the participating centres in Rome (Italy), Liège (Belgium) and Madrid (Spain). Primary endpoints were the efficacy and safety at 6 and 42 months from balloon positioning. Secondary endpoints included resolution of co-morbidities.
A total of 261 patients were included in this study. The most common indication for balloon placement was a psychological disorder (54 %). Mean body mass index (BMI) fell from 28.6 ± 0.4 at baseline to 25.4 ± 2.6 kg/m2 at 6 months and to 27.0 ± 3.1 kg/m2 at 3 years from BIB removal. The mean %EWL was 55.6 % at 6 months and 29.1 % at 3 years. Forty-seven patients (18 %) had complications associated with placement of the intragastric balloon (leak = 28, intolerance = 14, duodenal ulcer = 2, gastritis = 1, oesophagitis = 1, duodenal polyps = 1). The rate of patients with hypertension decreased from 29 % at baseline to 16 % at 3 years. Diabetes decreased from 15 to 10 %, dyslipidaemia decreased from 20 to 18 %, hypercholesterolaemia decreased from 32 to 21 % and osteoarthropathy decreased from 25 to 13 %.
The intragastric balloon is safe and effective in overweight patients, helping to reduce progression to obesity and decreasing the prevalence of a number of important co-morbidities.
KeywordsIntragastric balloon Obesity Overweight BMI %EWL Co-morbidities
- 1.World Health Organization. Factsheet: obesity and overweight. http://www.who.int/hpr/NPH/docs/gs_obesity.pdf.
- 2.Seidell JC. The impact of obesity on health status: some implications for health care costs. Int J Obesity. 1996;19 Suppl 6:S13–6.Google Scholar
- 6.Colditz GA, Willett WC, Rotnitsky A, et al. Weight gain as a risk factor for clinical diabetes in women. Arch Intern Med. 1995;122:481–6.Google Scholar
- 10.NIH Conference. Gastrointestinal surgery for severe obesity. Consensus development conference panel. Ann Intern Med. 1991;115:956–61.Google Scholar
- 21.Loveman E, Frampton GK, Shepherd J, et al. The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review. Health Technol Assess. 2011;15(2):1–182.Google Scholar
- 22.Pappachan JM, Chacko EC, Arunagirinathan G, et al. Management of hypertension and diabetes in obesity: non-pharmacological measures. Int J Hypertens. 2011;3:98–105.Google Scholar